Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine
Abstract
:1. Introduction
2. Methods
2.1. Participants
2.2. Methods and Materials
2.3. Statistical Analysis
3. Results
3.1. COVID-Naïve Status of All Subjects
3.2. S-Ab and N-Ab Responses
3.3. Regression Analysis
3.4. Estimation of Antibody Half-Lives
3.5. Age and Gender Group Analysis
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
SARS-CoV-2 | Severe acute respiratory syndrome coronavirus type 2 |
COVID-19 | Coronavirus disease 2019 |
Nuc-Ab | Nucleocapsid antibody |
S-Ab | Spike antibody |
N-Ab | Neutralizing antibody |
ELISA | Enzyme-linked immunoassay |
CLIA | Chemiluminescent immunoassay |
HCWs | Healthcare workers |
T-Ab | Total spike antibody |
ECLIA | Electro-chemiluminescent immunoassay |
COI | Cut-off index |
CI | Confidence interval |
References
- Favresse, J.; Elsen, M.; Eucher, C.; Laffineur, K.; Eeckhoudt, S.V.; Nicolas, J.B.; Gillot, C.; Dogne, J.M.; Douxfils, J. Long-term kinetics of anti-SARS-CoV-2 antibodies in a cohort of 197 hospitalized and non-hospitalized COVID-19 patients. Clin. Chem. Lab. Med. 2020, 59, e179–e183. [Google Scholar] [CrossRef]
- Favresse, J.; Eucher, C.; Elsen, M.; Gillot, C.; Eeckhoudt, S.V.; Dogne, J.M.; Douxfils, J. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. Microorganisms 2021, 9, 556. [Google Scholar] [CrossRef] [PubMed]
- Lau, C.S.; Phua, S.K.; Liang, Y.L.; Oh, M.L.H.; Aw, T.C. BNT162b2 mRNA COVID-19 Vaccine Elicited Antibody Responses in COVID-19-naïve Subjects. J. Exp. Pathol. 2021, 2, 117–127. [Google Scholar]
- Favresse, J.; Bayart, J.L.; Mullier, F.; Elsen, M.; Eucher, C.; Eeckhoudt, S.V.; Roy, T.; Wieers, G.; Laurent, C.; Dogne, J.M.; et al. Antibody titers decline 3-month post-vaccination with BNT162b2. Emerg. Microbes. Infect. 2021, 10, 1495–1498. [Google Scholar] [CrossRef]
- Grenache, D.G.; Ye, C.; Bradfute, S.B. Correlation of SARS-CoV-2 Neutralizing Antibodies to an Automated Chemiluminescent Serological Immunoassay. J. Appl. Lab. Med. 2021, 6, 491–495. [Google Scholar] [CrossRef]
- Piccoli, L.; Park, Y.J.; Tortorici, M.A.; Czudnochowski, N.; Walls, A.C.; Beltramello, M.; Silacci-Fregni, C.; Pinto, D.; Rosen, L.E.; Bowen, J.E.; et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell 2020, 183, 1024–1042. [Google Scholar] [CrossRef]
- Suhandynata, R.T.; Hoffman, M.A.; Huang, D.; Tran, J.T.; Kelner, M.J.; Reed, S.L.; McLawhon, R.W.; Voss, J.E.; Nemazee, D.; Fitzgerald, R.L. Commercial Serology Assays Predict Neutralization Activity against SARS-CoV-2. Clin. Chem. 2021, 67, 404–414. [Google Scholar] [CrossRef] [PubMed]
- Doria-Rose, N.; Suthar, M.S.; Makowski, M.; O’Connell, S.; McDermott, A.B.; Flach, B.; Ledgerwood, J.E.; Mascola, J.R.; Graham, B.S.; Lin, B.C.; et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for COVID-19. N. Engl. J. Med. 2021, 384, 2259–2261. [Google Scholar] [CrossRef]
- Lau, C.S.; Hoo, S.P.; Liang, Y.L.; Phua, S.K.; Aw, T.C. Performance of an automated chemiluminescent immunoassay for SARS-COV-2 IgM and head-to-head comparison of Abbott and Roche COVID-19 antibody assays. Pract. Lab. Med. 2021, 25, e00230. [Google Scholar]
- Lau, C.S.; Hoo, S.P.; Yew, S.F.; Ong, S.K.; Lum, L.T.; Heng, P.Y.; Tan, J.G.; Wong, M.S.; Aw, T.C. Evaluation of an Electrochemiluminescent SARS-CoV-2 Antibody Assay. J. Appl. Lab. Med. 2020, 5, 1313–1323. [Google Scholar] [CrossRef]
- Lau, C.S.; Oh, H.M.L.; Hoo, S.P.; Liang, Y.L.; Phua, S.K.; Aw, T.C. Performance of an automated chemiluminescence SARS-CoV-2 IG-G assay. Clin. Chim. Acta 2020, 510, 760–766. [Google Scholar] [CrossRef]
- SydPath Half-Life Calculator. Available online: http://www.sydpath.stvincents.com.au/other/HalfLifeCalculator.htm (accessed on 28 September 2021).
- World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013, 310, 2191–2194. [Google Scholar] [CrossRef] [Green Version]
- Levin, E.G.; Lusting, Y.; Cohen, C.; Fluss, R.; Indenbaum, V.; Amit, S.; Doolman, R.; Asraf, K.; Mendelson, E.; Ziv, A.; et al. Waning Immune Humoral Response to BNT162b2 COVID-19 Vaccine over 6 Months. N. Engl. J. Med. 2021, NEJMoa2114583, Online ahead of print. [Google Scholar] [CrossRef]
- Bayart, J.L.; Douxfils, J.; Gillot, C.; David, C.; Mullier, F.; Elsen, M.; Eucher, C.; Eeckhoudt, S.V.; Roy, T.; Gerin, V.; et al. Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers. Vaccines 2021, 9, 1092. [Google Scholar] [CrossRef]
- Khoury, D.S.; Cromer, D.; Reynaldi, A.; Schlub, T.E.; Wheatley, A.K.; Juno, J.A.; Subbarao, K.; Kent, S.J.; Triccas, J.A.; Davenport, M.P. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 2021, 27, 1205–1211. [Google Scholar] [CrossRef]
- Favresse, J.; Gillot, C.; Chiaro, L.D.; Eucher, C.; Elsen, M.; Eeckhoudt, S.V.; David, C.; Morimont, L.; Dogne, J.M.; Douxfils, J. Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2. Viruses 2021, 13, 1364. [Google Scholar] [CrossRef]
- Roltgen, K.; Nielsen, S.C.A.; Arunachalam, P.S.; Yang, F.; Hoh, R.A.; Wirz, O.F.; Lee, A.S.; Gao, F.; Mallajosyula, V.; Li, C.; et al. mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition. medRxiv 2021. [Google Scholar] [CrossRef]
- Long, Q.X.; Liu, B.Z.; Deng, H.J.; Wu, G.C.; Deng, K.; Chen, Y.K.; Liao, P.; Qiu, J.F.; Lin, Y.; Cai, X.F.; et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 2020, 26, 845–848. [Google Scholar] [CrossRef]
- Wei, J.; Stoesser, N.; Matthews, P.C.; Ayoubkhani, D.; Studley, R.; Bell, I.; Bell, J.I.; Newton, J.N.; Farrar, J.; Diamond, I.; et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat. Microbiol. 2021, 6, 1140–1149. [Google Scholar] [CrossRef]
- Demonbreun, A.R.; Sancilio, A.; Velez, M.P.; Ryan, D.T.; Saber, R.; Vaµght, L.A.; Reiser, N.L.; Hsieh, R.R.; D’Aquila, R.T.; Mustanski, B.; et al. Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals. EClinicalMedicine. 2021, 38, 101018. [Google Scholar] [CrossRef] [PubMed]
- Steensels, D.; Pierlet, N.; Penders, J.; Mesotten, D.; Heylen, L. Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273. JAMA 2021, 326, 1533–1535. [Google Scholar] [CrossRef]
- Thompson, M.G.; Stenehjem, E.; Grannis, S.; Ball, S.W.; Naleway, A.L.; Ong, T.C.; DeSilva, M.B.; Natarajan, K.; Bozio, C.H.; Lewis, N.; et al. Effectiveness of COVID-19 Vaccines in Ambulatory and Inpatient Care Settings. N. Engl. J. Med. 2021, 385, 1355–1371. [Google Scholar] [CrossRef] [PubMed]
- Jalkanen, P.; Kolehmainen, P.; Hakkinen, H.K.; Huttunen, M.; Tahtinen, P.A.; Lundberg, R.; Maljanen, S.; Reinholm, A.; Tauriainen, S.; Pakkanen, S.H.; et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat. Commun. 2021, 12, 3991. [Google Scholar] [CrossRef]
- Tretyn, A.; Szczepanek, J.; Skorupa, M.; Jarkiewicz-Tretyn, J.; Sandomierz, D.; Dejewska, J.; Ciechanowska, K.; Jarkiewicz-Tretyn, A.; Koper, W.; Palgan, K. Differences in the Concentration of Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 Recovery or Post-Vaccination. Cells 2021, 10, 1952. [Google Scholar] [CrossRef]
- Elslande, J.V.; Gruwier, L.; Godderis, L.; Vermeersch, P. Estimated half-life of SARS-CoV-2 anti-spike antibodies more than double the half-life of anti-nucleocapsid antibodies in healthcare workers. Clin. Infect. Dis. 2021, ciab219, Online ahead of print. [Google Scholar] [CrossRef]
- Gaebler, C.; Wang, Z.; Lorenzi, J.C.C.; Muecksch, F.; Finkin, S.; Tokuyama, M.; Tokuyama, M.; Cho, A.; Jankovic, M.; Schaefer-Babajew, D.; et al. Evolution of antibody immunity to SARS-CoV-2. Nature 2021, 591, 639–644. [Google Scholar] [CrossRef]
- Wheatley, A.K.; Juno, J.A.; Wang, J.J.; Selva, K.J.; Reynaldi, A.; Tan, H.X.; Lee, W.S.; Wragg, K.M.; Kelly, H.G.; Esterbauer, R.; et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat. Commun. 2021, 12, 1162. [Google Scholar] [CrossRef]
- Dan, J.M.; Mateus, J.; Kato, Y.; Hastie, K.M.; Yu, E.D.; Faliti, C.E.; Grifoni, A.; Ramirez, S.I.; Haupt, S.; Frazier, A.; et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021, 371, eabf4063. [Google Scholar] [CrossRef]
- Goel, R.R.; Apostolidis, S.A.; Painter, M.M.; Mathew, D.; Pattekar, A.; Kuthuru, O.; Gouma, S.; Hicks, P.; Meng, W.; Rosenfeld, A.M.; et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci. Immunol. 2021, 6, eabi6950. [Google Scholar] [CrossRef]
- Muller, L.; Andree, M.; Moskorz, W.; Drexler, I.; Walotka, L.; Grothmann, R.; Ptok, J.; Hillebrandt, J.; Ritchie, A.; Rabl, D.; et al. Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination. Clin. Infect. Dis 2021, ciab381, Online ahead of print. [Google Scholar] [CrossRef]
Days Post-Vaccination | 20 | 40 | 60 | 90 | 120 | 150 | 180 | Half-Life | Days to N-Ab Cut-Off * |
---|---|---|---|---|---|---|---|---|---|
Total (U/mL) | 2482 | 2127 | 1822 | 1445 | 1146 | 909 | 721 | 90 days | 470 |
IgG (AU/mL) | 18,560 | 12,194 | 8012 | 4267 | 2272 | 1210 | 644 | 33 days | 163 |
N-Ab (µg/mL) | 4.64 | 3.63 | 2.83 | 1.95 | 1.35 | 0.93 | 0.64 | 56 days | 241 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lau, C.-S.; Phua, S.K.; Liang, Y.-L.; Oh, H.M.-L.; Aw, T.-C. Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine. Vaccines 2021, 9, 1241. https://doi.org/10.3390/vaccines9111241
Lau C-S, Phua SK, Liang Y-L, Oh HM-L, Aw T-C. Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine. Vaccines. 2021; 9(11):1241. https://doi.org/10.3390/vaccines9111241
Chicago/Turabian StyleLau, Chin-Shern, Soon Kieng Phua, Ya-Li Liang, Helen May-Lin Oh, and Tar-Choon Aw. 2021. "Robust SARS-CoV-2 Antibody Responses in Asian COVID-Naïve Subjects 180 Days after Two Doses of BNT162b2 mRNA COVID-19 Vaccine" Vaccines 9, no. 11: 1241. https://doi.org/10.3390/vaccines9111241